These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Short-term changes in choroidal thickness after aflibercept therapy for neovascular age-related macular degeneration. Koizumi H; Kano M; Yamamoto A; Saito M; Maruko I; Kawasaki R; Sekiryu T; Okada AA; Iida T Am J Ophthalmol; 2015 Apr; 159(4):627-33. PubMed ID: 25555799 [TBL] [Abstract][Full Text] [Related]
4. Choroidal Thickness Changes in Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy: A 12-Month Prospective Study. Ting DS; Ng WY; Ng SR; Tan SP; Yeo IY; Mathur R; Chan CM; Tan AC; Tan GS; Wong TY; Cheung CM Am J Ophthalmol; 2016 Apr; 164():128-36.e1. PubMed ID: 26743619 [TBL] [Abstract][Full Text] [Related]
5. Correlation between neovascular lesion type and clinical characteristics of nonneovascular fellow eyes in patients with unilateral, neovascular age-related macular degeneration. Marsiglia M; Boddu S; Chen CY; Jung JJ; Mrejen S; Gallego-Pinazo R; Freund KB Retina; 2015 May; 35(5):966-74. PubMed ID: 25627089 [TBL] [Abstract][Full Text] [Related]
6. Association between choroidal thickness and the response to intravitreal ranibizumab injection in age-related macular degeneration. Shin JY; Kwon KY; Byeon SH Acta Ophthalmol; 2015 Sep; 93(6):524-32. PubMed ID: 25581639 [TBL] [Abstract][Full Text] [Related]
7. Subfoveal choroidal thickness in polypoidal choroidal vasculopathy after switching to intravitreal aflibercept injection. Saito M; Kano M; Itagaki K; Ise S; Imaizumi K; Sekiryu T Jpn J Ophthalmol; 2016 Jan; 60(1):35-41. PubMed ID: 26350229 [TBL] [Abstract][Full Text] [Related]
8. Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration. Kang HM; Kwon HJ; Yi JH; Lee CS; Lee SC Am J Ophthalmol; 2014 May; 157(5):1013-21. PubMed ID: 24487050 [TBL] [Abstract][Full Text] [Related]
9. Prognostic factors after aflibercept therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy. Ogasawara M; Koizumi H; Yamamoto A; Itagaki K; Saito M; Maruko I; Okada AA; Iida T; Sekiryu T Jpn J Ophthalmol; 2018 Sep; 62(5):584-591. PubMed ID: 29974277 [TBL] [Abstract][Full Text] [Related]
10. Aflibercept therapy for polypoidal choroidal vasculopathy: short-term results of a multicentre study. Koizumi H; Kano M; Yamamoto A; Saito M; Maruko I; Sekiryu T; Okada AA; Iida T Br J Ophthalmol; 2015 Sep; 99(9):1284-8. PubMed ID: 25777816 [TBL] [Abstract][Full Text] [Related]